SPDR S&P Biotech ETF (NYSEARCA:XBI) Hits New 12-Month High – Should You Buy?

by · The Markets Daily

SPDR S&P Biotech ETF (NYSEARCA:XBI – Get Free Report) shares hit a new 52-week high during trading on Thursday . The company traded as high as $103.89 and last traded at $103.27, with a volume of 1307776 shares trading hands. The stock had previously closed at $102.44.

SPDR S&P Biotech ETF Trading Up 0.7 %

The business has a 50 day simple moving average of $98.86 and a two-hundred day simple moving average of $95.33. The stock has a market cap of $7.86 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Hartline Investment Corp grew its position in shares of SPDR S&P Biotech ETF by 2.0% in the 3rd quarter. Hartline Investment Corp now owns 5,502 shares of the exchange traded fund’s stock worth $544,000 after acquiring an additional 106 shares in the last quarter. HBK Sorce Advisory LLC boosted its holdings in SPDR S&P Biotech ETF by 2.6% in the first quarter. HBK Sorce Advisory LLC now owns 4,538 shares of the exchange traded fund’s stock worth $431,000 after purchasing an additional 113 shares during the period. Intellectus Partners LLC increased its stake in SPDR S&P Biotech ETF by 1.0% during the second quarter. Intellectus Partners LLC now owns 11,334 shares of the exchange traded fund’s stock valued at $1,051,000 after purchasing an additional 113 shares during the last quarter. Pacific Center for Financial Services raised its holdings in shares of SPDR S&P Biotech ETF by 2.8% during the first quarter. Pacific Center for Financial Services now owns 4,359 shares of the exchange traded fund’s stock worth $414,000 after purchasing an additional 118 shares during the period. Finally, Signature Estate & Investment Advisors LLC lifted its position in shares of SPDR S&P Biotech ETF by 5.7% in the 3rd quarter. Signature Estate & Investment Advisors LLC now owns 2,336 shares of the exchange traded fund’s stock worth $231,000 after buying an additional 125 shares during the last quarter.

SPDR S&P Biotech ETF Company Profile

(Get Free Report)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

See Also